Zai Lab Limited American Depositary Shares (ZLAB) is a publicly traded Healthcare sector company. As of May 21, 2026, ZLAB trades at $18.44 with a market cap of $2.12B and a P/E ratio of -108.98. ZLAB moved +2.29% today. Year to date, ZLAB is +3.98%; over the trailing twelve months it is -42.35%. Its 52-week range spans $15.96 to $44.34. Analyst consensus is strong buy with an average price target of $34.27. Rallies surfaces ZLAB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Zai Lab Wins FDA Fast Track for DLL3-Targeting Zocilurtatug Pelitecan in epNECs: Zai Lab’s DLL3-targeting antibody-drug conjugate Zocilurtatug Pelitecan has secured U.S. FDA Fast Track designation for treating extrapulmonary neuroendocrine carcinomas. The designation aims to expedite development and review processes, potentially accelerating Zai Lab’s clinical timeline for this epNEC therapy.
| Metric | Value |
|---|---|
| Price | $18.44 |
| Market Cap | $2.12B |
| P/E Ratio | -108.98 |
| EPS | $-0.17 |
| Dividend Yield | 0.00% |
| 52-Week High | $44.34 |
| 52-Week Low | $15.96 |
| Volume | 151 |
| Avg Volume | 0 |
| Revenue (TTM) | $453.28M |
| Net Income | $-178.12M |
| Gross Margin | 58.00% |
4 analysts cover ZLAB: 0 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $34.27.